Table 2.
Secondary efficacy outcomes
| EDSS | Placebo N = 17 | AP N = 20 | p |
|---|---|---|---|
| Baseline median EDSS | 6.0 (2.5–7.0) | 6.0 (3.5–7.5) | 0.92 |
| Final median EDSS | 6.5 (2.0–8.0) | 6.0 (3.0–7.5) | 0.24 |
| Baseline mean EDSS | 5.7 ± 1.3 | 5.8 ± 1.1 | 0.93 |
| Final mean EDSS | 6.2 ± 1.3 | 5.8 ± 1.3 | 0.43 |
| Mean EDSS change | + 0.35 (95% CI, −0.75 - 0.05) | −0.03 (95% CI, − 0.4 - 0.4) | 0.04a |
| Other efficacy outcomes | PlaceboN = 17 | APN = 20 | p |
| mean change (95% CI) | mean change (95% CI) | ||
| SDMT | 0.49 (0.05–0.92) | 0.23 (−0.13–0.59) | 0.36 |
| PASAT | 0.28 (−0.57–1.09) | 0.22 (− 0.44–0.89) | 0.92 |
| 9HPT | 0.01 (−2.18–2.16) | −1.55 (−3.65–0.54) | 0.32 |
| T25FW | 1.58 (−5.39–8.56) | −1.19 (−7.15–4.77) | 0.56 |
| MSFC | 0.05 (−0.19–0.29) | 0.11 (− 0.62–0.29) | 0.69 |
| RNFL | −9.2 (− 12.9–5.5) | −7.3 (− 11.2–3.3) | 0.47 |
aAdjusted model (baseline EDSS as a covariate); the mean difference between AP and placebo was 0.63
SMDT: symbol digit modalities test; PASAT Paced auditory serial addition test; 9HPT Nine-hole peg test; T25FW Timed 25-ft walk; MSFC Multiple sclerosis functional composite; RNFL Retinal nerve fibre layer. The results from GLM were adjusted for baseline MSFC